New CMS reimbursement rates are pressuring Medicare Advantage profits, sending shares of Humana and CVS Health lower. We analyze whether the sell-off presents a buying opportunity for dividend investors or signals deeper structural challenges.
A week of significant stock swings saw Lockheed Martin and Texas Instruments surge on strong outlooks, while Humana plunged on regulatory headwinds. Here’s what drove the action and what analysts are saying.
Facing a significant stock decline and a challenging Medicare Advantage outlook, UnitedHealth Group announces leadership changes and a 'Back to Basics' operational reset, aiming to stabilize its core business amid shifting market dynamics.
The healthcare sector has surged 17.4% in six months, outpacing the S&P 500. While demographic trends fuel long-term growth, regulatory hurdles and valuation concerns demand selective investing. We analyze one company built for decades of returns and two where investors should tread carefully.
A proposed near-zero payment increase for Medicare Advantage plans by the Trump administration has blindsided Wall Street, erasing billions in market value and raising fears of a prolonged downturn for major health insurers.
